CASI Pharmaceuticals - Evomela sales going strong into 2021
CASI has announced as part of its preliminary results that it sold $4.8m worth of Evomela in Q420 and approximately $15m for the year (unaudited), exceeding the company guidance of $14m and our estimate of $14.4m. The company stated that it is targeting 50% growth in Evomela sales in 2021. Additionally, in 2021 the company will be jump starting its clinical development engine as it is expected to initiate clinical studies on a majority of its portfolio during the year.CASI Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing therapeutics and pharmaceutical products. The company's primary product and candidates in hematology/oncology include: EVOMELA (Melphalan for Injection), an intravenous formulation of melphalan commercialized in the multiple myeloma treatment setting in the United States; CNCT19, which targets CD19, a B-cell surface protein expressed during all phases of B-cell development and a validated target for B-cell driven hematological malignancies; CID-103, an investigational anti-CD38 monoclonal antibody being developed for the treatment of patients with multiple myeloma.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.